EGFR and neoplasm: Additionally, tumor cells exploit PD-L1 to suppress T cell recognition, while aberrant EGFR signaling and cell cycle dysregulation promote cell proliferation (Glaviano et al., 2024; Saxena & Dwivedi, 2012; Vathiotis et al., 2022).